SureTrader SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Miscellaneous >

EP Global Communications, Inc. (EPGL)

EPGL RSS Feed
Add EPGL Price Alert      Hide Sticky   Hide Intro
Moderator: Atlanta1, flaflyersfan, integral, Stock Barber
Search This Board: 
Last Post: 2/22/2017 12:21:04 PM - Followers: 477 - Board type: Free - Posts Today: 14

 EPGL  


People, Products & Process:
EPGL has assembled an impressive team to propel the company into a bright future and to build shareholder value. Under the leadership of Michael Hayes EPGL underwent debt restructuring, assembly of a new management team, as well as medical and scientific personnel. Mr. Hayes has made it a singular priority to bring aboard only the world’s top professionals in the field of medical sciences to EPGL and thereby build the Company into a major player in the Medical Device Industry over the next several years. He has also committed to prioritizing shareholders and creating significant value for their investment over time. We have seen great evidence of the har work over the last couple years as EPGL has signed Development Agreements with CooperVision, Intel, and AT&T. EPGL is in negotiations to licence technology to CooperVision presently. On April 28th 2015, EPGL disclosed to shareholders that
EPGL and AT&T have created joint Intellectual Properties and are now in the process of procuring those properties. Shareholders can expect developments on this in the near future.


One key team member that was brought on board is David Markus (Vice President, BioMEMS) Developer, As you will see David Markus is a Well Accomplished Engineer.

David T. Markus holds a Ph.D. in Biomedical Engineering and a MS in Electrical Engineering with an emphasis in MEMS Microelectronics and Biomedical. Dr. Markus spent 11 years with Raytheon and holds 8 US patents and has 9 other US Patents Pending. He has been involved in research for several of the world's leading technological institutions, including the Office of Naval Research in Arlington, Virginia, NASA Jet Propulsion Laboratory in Pasadena, CA and he has been published 15 times for various technical conferences. He was a principal investigator on SBIR DARPA Phase I and Phase II, and "Ultraflexible Substrate" for Macroelectronics Program by Dr. Robert Reuss at DARPA. He has been involved in the engineering and the development on seven surgical devices, including devices for Cataract surgery, Intra-Ocular Lens Delivery, Arthroscopy, Endodontic Endoscope, Micro Endoscope and Neural Electrodes. Additionally he was instrumental on developing three medical laboratory devices, including for In-Vitro Fertilization, PCR instrumentation and drug discovery.

The Company claims to have significant know-how and Intellectual Property in the arena of BioMEMS and claims to have invented new device technologies which include, but are not limited to the following:
 
1. Advanced Power Source for Contact Lenses 11. Advanced TopSpin Platform Technology for Development of Smart Medical Devices
2. Advanced Cell Regeneration Technology to Treat Eye Disease 12. Advanced Device for Steam Cell Treatment Delivery
3. Advanced Cell Regeneration Technology to Treat Hearing Loss 13. Advanced Device for Treatment of Prostate Tumors
4. Advanced Nerve Ablation Device 14. Advanced Endoscopic Device
5. Advanced Epidural Device 15. Advanced Device for Delievery of Micron Sized Drug Payloads
6. New & Promsing Treatment of Restinitis Pigmentosa 16. New & Promising Device for Treatment of Macular Degeneration
7. Advanced Ablation Device for Nerve Treatment of Facial Glabballar Frownig 17. New Advanced Contact Lens Device
8. New Advanced PowerSource for TopSpin Medical Devices 18. Advanced Device For Delivery of Micro Mechanical Devices Into Body
9. Advanced Trigger Point Needle Device 19.  Device for  Advanced Biopsy
10. Advanced Micron Resolution Motor for Smart Medical Devices 20. Real-Time Sensor Technologies for Connectivity to a Global Network  **NEW
21.Real-Time Data Applications for Athletic Teams, Workforces and Military Forces*NEW
 


About EPGL Medical Science's Share Structure :

EPGL has a share structure of 5 billion authorized shares with approximately 4.5 billion shares restricted and a float of approximately 499 million. Following a very successful Reverse Split EPGL has decreased the float by 90% and increased share holder value by over 500% since that time. The company has strongly stated many times that they will not sell shares into the retail market. They are here to build a real company and implement real growth. Since restructuring EPGL has not increased the Float/OS/AS and have given us there word on countless occasions they will not do so.

Pricewaterhouse Coopers, Corporate Finance and Recovery (Cayman) Ltd.Controlling Agent for:
AJW Qualified Partners, LLC, Controlled by PwC (PricewaterhouseCoopers) - Court appointed
1.975 Billion Common Shares
Mr. Michael Hayes
1.975 Billion Common Shares
FLOAT/TRADABLE SHARES : 499 Million ***Unchanged since Restructure in 2012***
Total number of shareholders of record 700 approximate 

ISSUERS FACILITIES
The Company claims to have leases or utilizes facilities in the following locations

Various California Bay Area Research Facilities Under NDA, David T. Markus, Ph.D.

Irvine, California – Research Facilities, Office

New York University Langone Medical Center, Corey W. Hunter M.D. / Eric Lee M.D.

University of Minnesota, David T. Markus, Ph.D.

University of California at Irvine, David T. Markus, Ph.D.

Dallas and Plano Texas, David T. Markus, Ph.D. **NEW**


Follow EPGL on the WEB at http://www.epglmed.com







 

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
EPGL
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#115166  Sticky Note EPGL Gains Third US Patent Allowance and InWith vikingzskillz 01/31/17 07:01:02 PM
#108787  Sticky Note EPGL Wins Allowance on First Patent vikingzskillz 08/30/16 10:08:17 PM
#95482  Sticky Note Press releases or other company communication should not IH Brian (Retired) 01/12/16 12:14:18 PM
#116232   Nothing yet Hyd 02/22/17 12:38:49 PM
#116231   Most of companies use these sentences. franck92 02/22/17 12:21:03 PM
#116230   Management Atlanta1 02/22/17 12:16:07 PM
#116229   Quaterly report franck92 02/22/17 12:13:07 PM
#116228   Suggest going directly to InWith and pickup free AJCash 02/22/17 11:51:56 AM
#116227   Check for info on the new start-up's website: Donguri 02/22/17 11:34:31 AM
#116226   Did everybody that elected to receive gift offer WhymeMA 02/22/17 11:29:41 AM
#116225   Yep, Sell lower guys, Lol, Do it. franck92 02/22/17 11:27:22 AM
#116224   Yep H8ster,something to consider. Donguri 02/22/17 11:21:32 AM
#116223   New patent on the way. Somebody wants H8ster 02/22/17 11:13:30 AM
#116217   Yep, finally all gaps hit! Time for UP! vikingzskillz 02/21/17 10:15:59 PM
#116216   except they have not validated patents, no technologies franck92 02/21/17 09:06:58 PM
#116215   The only people you see buying here are rostam92 02/21/17 09:02:08 PM
#116214   Good but not excellent. stock performance today is allegiant 02/21/17 07:18:04 PM
#116212   It actually traded at 2 pennies today... Stock Barber 02/21/17 05:12:25 PM
#116211   Who's being meek? At under 3 pennies there's skorz 02/21/17 05:03:50 PM
#116210   Yup! Good stuff ahead! Let's continue to H8ster 02/21/17 04:32:18 PM
#116209   Retirement planning on a Tweet, whats next. AJCash 02/21/17 04:24:48 PM
#116208   And if InWith doesn't raise the capital, what AJCash 02/21/17 04:05:44 PM
#116207   If you read the tweet the ground, the franck92 02/21/17 04:00:10 PM
#116206   It would be nice to know there is Hank Kerchief 02/21/17 03:54:35 PM
#116205   Me too, I don't understand the confusion? Scutterflux 02/21/17 03:52:34 PM
#116204   For the moment it is said by a franck92 02/21/17 03:46:24 PM
#116203   Better yet, show us the money to substantiate AJCash 02/21/17 03:43:46 PM
#116202   SO SHOW US THE FORMAL OFFER ??? AJCash 02/21/17 03:40:12 PM
#116201   Not" as high" but IS 9.8 cents franck92 02/21/17 03:36:43 PM
#116200   There is NO FIRM OFFER, only a possible AJCash 02/21/17 03:35:29 PM
#116199   "The offer is 9.8 cents / share....." franck92 02/21/17 03:33:19 PM
#116198   THE OFFER could be ONLY .001 cents AJCash 02/21/17 03:27:53 PM
#116195   The offer depends on raising money but the franck92 02/21/17 03:17:50 PM
#116194   Actually, here it is ..."EPGL vote to approve Stentor1 02/21/17 03:13:37 PM
#116193   Im quite sure its dependent on raising a Stentor1 02/21/17 03:10:20 PM
#116191   so why is the stock trading at .0229? Atlanta1 02/21/17 03:00:10 PM
#116190   "The offer is 9.8 cents / share OR franck92 02/21/17 02:57:39 PM
#116189   So, concerning the 'buy out", I imagine they Stentor1 02/21/17 02:49:38 PM
#116188   Share price reflects reality; EPGL going down. AJCash 02/21/17 01:58:00 PM
#116187   Going below 2 cents before March. AJCash 02/21/17 01:55:23 PM
#116186   EPGL doesn't control the share price, it's Scutterflux 02/21/17 01:40:40 PM
#116185   I'm not investing based on the last week Scutterflux 02/21/17 01:37:01 PM
#116184   Based on annual financials as a company EPGL skorz 02/21/17 01:35:15 PM
#116181   You don't need to know me to read MarkHart66 02/21/17 01:09:17 PM
#116180   Yes PCT should mean it is an international franck92 02/21/17 12:35:10 PM
#116178   I may be confused because there were 2 judypudy 02/21/17 12:25:11 PM
#116177   The fact there are validated patents AND JNJ franck92 02/21/17 12:15:45 PM
#116176   I just sat here and read all the MarkHart66 02/21/17 12:04:11 PM
#116175   I bet for PIEZOELECTRIC ENERGY HARVESTING CONTACT LENS franck92 02/21/17 12:02:57 PM
#116174   So it would be the third if the franck92 02/21/17 12:00:53 PM
#116173   They announced that one in their last PR. wobblenuts 02/21/17 11:57:34 AM
#116172   I think EPGL's 4th Patent is it's Auto Focus. judypudy 02/21/17 11:51:10 AM
#116171   Soon we will know the Inwith team and franck92 02/21/17 11:26:06 AM
PostSubject